ClinicalTrials.gg
CompletedNCT02039765Updated Apr 28, 2017

Pharmacokinetics and Safety of Topical Administration of Brimonidine Tartrate Ophthalmic Solution 0.025%.

A Phase 1 interventional study of Brimonidine tartrate in Hyperemia, sponsored by Bausch & Lomb Incorporated. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-04-28.

Sponsored by Bausch & Lomb Incorporated (part of Bausch Health Companies Inc.) · Phase 1, Interventional, and Screening

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
12
Allocation
Not applicable
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 23 studies in Hyperemia with a site in United States — 9 open to participants now, 9 under way, 2 of them phase 3. Hyperemia · United States.

Enrollment
17th of 19
12 · median 68
Started
2014
with 2 others
Phase 1
3 of 23
1 open now
Registered
5th of 23
by date
Lead sponsor
3 of 23
Bausch & Lomb Incorporated

Among the 23 studies in Hyperemia with a site in United States, this one is the 17th largest by enrollment of the 19 interventional ones that give a count, is one of 3 that started in 2014, is one of 3 in phase 1, and was the 5th registered.

Hyperemia

98 studies on the registry are indexed under Hyperemia; 44 are open to participants now.

Browse Hyperemia studies →

Open to participants now

9 of the 23 studies in Hyperemia with a site in United States are open now. Recruiting first, the newest first:

4 more — sign in →

All 9 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 28 Hyperemia studies recruiting now, 17 (61%) set no upper age limit and 7 (25%) stop at 75 or younger; 2 take children under 18; 3 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Hyperemia with a site in United States, or all of them as a file.
02

Study summary

To characterize the plasma pharmacokinetics and safety profile of brimonidine following a single dose and 4 times per day (QID) dosing of brimonidine tartrate ophthalmic solution 0.025% for 7 days in healthy, adult subjects.

03

Conditions studied

  • Hyperemia

Browse trials for

Keywords

  • Ocular Redness
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • have ocular health within normal limits.
  • have blood (hematology, blood chemistry) and urine analysis within normal limits.
  • have a body weight within 15% of ideal weight

Exclusion criteria

Exclusion Criteria:

  • have known or sensitivity to the use of any of the drug(s) or their components, or any other medications required by the protocol;
  • have any active systemic or ocular disorder other than refractive disorder.
  • have presence of any abnormality of the lids, ocular surface, or lacrimal duct system that in the Investigator's opinion could affect ophthalmic drop absorption.
  • have a history of chronic alcohol consumption.
  • consume alcohol and/or caffeine or xanthine containing products within 48 hours prior to dosing at Visit 1 or anticipated use during the study.
  • have a history of tobacco, nicotine, or nicotine containing product use within the last year prior to Visit 2;
  • have significant weight change (over 10 pounds) within the 60 days prior to Visit 2;
  • have blood donation or equivalent blood loss of 450 ml or more, within 60 days prior to Visit 2;
  • have an abnormal blood pressure (defined as ≤ 90 or ≥ 160 (systolic) measured in mmHg or ≤ 60 or ≥ 100 (diastolic) measured in mmHg);
  • have intraocular pressure (IOP) that is less than 5 mmHg or greater than 22 mmHg or have a normal IOP with a diagnosis of glaucoma.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Screening
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    Brimonidine tartrate

    One drop of brimonidine tartrate ophthalmic solution 0.025% in each eye once at Visit 2 (Day 1) then four times daily (QID) approximately 4 hours apart at Visit 3 (Day 2) through day 6, and then once at Visit 4 (Day 7).

    Drug: Brimonidine tartrate

Interventions

06

What researchers measure

Primary outcomes

  1. Plasma Levels

    Blood samples will be collected for the determination of brimonidine in plasma at the specified time points on Day 1.

    Time frame: Day 1 (Visit 2)

  2. Plasma Levels

    Blood samples will be collected for the determination of brimonidine in plasma at the specified time points on Day 2.

    Time frame: Day 2 (Visit 3)

  3. Plasma Levels

    Blood samples will be collected for the determination of brimonidine in plasma at the specified time points on Day 7.

    Time frame: Day 7 (Visit 4)

  4. Plasma Levels

    Blood samples will be collected for the determination of brimonidine in plasma at the specified time points on Day 8.

    Time frame: Day 8 (Visit 5)

Secondary outcomes

  1. Visual Acuity

    Visual acuity testing should be done with best correction at 10ft

    Time frame: Baseline (Visit 1)

  2. Slit Lamp Biomicroscopy

    Lid and lid margin erythema and swelling, conjunctival erythema/hyperemia and chemosis will be graded on a scale of 0 - 4. with 0=normal and 4=marked. Half grade measurements will be accepted for erythema/hyperemia.

    Time frame: Baseline (Visit 1)

  3. Intraocular Pressure

    Intraocular Pressure measured at baseline Day 8 (Visit 5)

    Time frame: Day 8 (Visit 5)

  4. Hematology and Blood Chemistry Analysis

    Blood samples will be collected for hematology and blood chemistry parameters at Baseline (Visit 1)

    Time frame: Baseline (Visit 1)

  5. Urinalysis

    Urine sample will be collected for urinalysis at Baseline (Visit 1)

    Time frame: Baseline (Visit 1)

  6. Visual Acuity

    Visual acuity testing should be done with best correction at 10ft

    Time frame: Day 1 (Visit 2)

  7. Visual Acuity

    Visual acuity testing should be done with best correction at 10ft

    Time frame: Day 7 (Visit 4)

  8. Visual Acuity

    Visual acuity testing should be done with best correction at 10ft

    Time frame: Day 8 (Visit 5)

  9. Slit Lamp Biomicroscopy

    Lid and lid margin erythema and swelling, conjunctival erythema/hyperemia and chemosis will be graded on a scale of 0 - 4. with 0=normal and 4=marked. Half grade measurements will be accepted for erythema/hyperemia.

    Time frame: Day 1 (Visit 2)

  10. Slit Lamp Biomicroscopy

    Lid and lid margin erythema and swelling, conjunctival erythema/hyperemia and chemosis will be graded on a scale of 0 - 4. with 0=normal and 4=marked. Half grade measurements will be accepted for erythema/hyperemia.

    Time frame: Day 7 (Visit 4)

  11. Slit Lamp Biomicroscopy

    Lid and lid margin erythema and swelling, conjunctival erythema/hyperemia and chemosis will be graded on a scale of 0 - 4. with 0=normal and 4=marked. Half grade measurements will be accepted for erythema/hyperemia.

    Time frame: Day 8 (Visit 5)

  12. Intraocular Pressure

    Intraocular Pressure measured at baseline (Visit 1)

    Time frame: Baseline (Visit 1)

  13. Hematology and Blood Chemistry Analysis

    Blood samples will be collected for hematology and blood chemistry parameters at Day 8 (Visit 5)

    Time frame: Day 8 (Visit 5)

  14. Urinalysis

    Urine sample will be collected for urinalysis at Day 8 (Visit 5)

    Time frame: Day 8 (Visit 5)

07

Study locations

1 site
  • Bausch & Lomb, Incorporated
    Rochester, New York 14609, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2014 to primary completion in Mar 2014, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 16, 2014
First posted
Jan 20, 2014
StartActual
Feb 2014
Primary completionActual
Mar 2014
CompletionActual
Apr 2014
Last update
Apr 28, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 28, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02039765
Collaborators
ORA, Inc.
Responsible party
Sponsor
First posted
Jan 20, 2014
Start date
Feb 2014
Primary completion
Mar 2014
Completion
Apr 2014
Last update
Apr 28, 2017

Study contacts

Joseph Ciolino, MD
study director · ORA, Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Brimonidine

Start the discussion